Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients : Implications for Adaptive Dosing Strategies
© 2023. The Author(s)..
BACKGROUND AND OBJECTIVES: Isavuconazole is a broad-spectrum antifungal agent for the management of invasive fungal disease. Optimised drug exposure is critical for patient outcomes, specifically in the critically ill population. Solid information on isavuconazole pharmacokinetics including protein binding in patients in the intensive care unit is scarce. We aimed to describe the total and unbound isavuconazole pharmacokinetics and subsequently propose a dosage optimisation strategy.
METHODS: A prospective multi-centre study in adult intensive care unit patients receiving isavuconazole was performed. Blood samples were collected on eight timepoints over one dosing interval between days 3-7 of treatment and optionally on one timepoint after discontinuation. Total and unbound isavuconazole pharmacokinetics were analysed by means of population pharmacokinetic modelling using NONMEM. The final model was used to perform simulations to assess exposure described by the area under the concentration-time curve and propose an adaptive dosing approach.
RESULTS: Population pharmacokinetics of total and unbound isavuconazole were best described by an allometrically scaled two-compartment model with a saturable protein-binding model and interindividual variability on clearance and the maximum binding capacity. The median (range) isavuconazole unbound fraction was 1.65% (0.83-3.25%). After standard dosing, only 35.8% of simulated patients reached a total isavuconazole area under the concentration-time curve > 60 mg·h/L at day 14. The proposed adaptive dosing strategy resulted in an increase to 62.3% of patients at adequate steady-state exposure.
CONCLUSIONS: In critically ill patients, total isavuconazole exposure is reduced and protein binding is highly variable. We proposed an adaptive dosing approach to enhance early treatment optimisation in this high-risk population.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04777058.
| Errataetall: |
CommentIn: Clin Pharmacokinet. 2024 Apr 4;:. - PMID 38573478 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Clinical pharmacokinetics - 62(2023), 12 vom: 10. Dez., Seite 1701-1711 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jansen, Anouk M E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
60UTO373KE |
|---|
| Anmerkungen: |
Date Completed 29.11.2023 Date Revised 16.04.2024 published: Print-Electronic ClinicalTrials.gov: NCT04777058 CommentIn: Clin Pharmacokinet. 2024 Apr 4;:. - PMID 38573478 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s40262-023-01305-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363125922 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363125922 | ||
| 003 | DE-627 | ||
| 005 | 20240416232317.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40262-023-01305-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1377.xml |
| 035 | |a (DE-627)NLM363125922 | ||
| 035 | |a (NLM)37819503 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jansen, Anouk M E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients |b Implications for Adaptive Dosing Strategies |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.11.2023 | ||
| 500 | |a Date Revised 16.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04777058 | ||
| 500 | |a CommentIn: Clin Pharmacokinet. 2024 Apr 4;:. - PMID 38573478 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a BACKGROUND AND OBJECTIVES: Isavuconazole is a broad-spectrum antifungal agent for the management of invasive fungal disease. Optimised drug exposure is critical for patient outcomes, specifically in the critically ill population. Solid information on isavuconazole pharmacokinetics including protein binding in patients in the intensive care unit is scarce. We aimed to describe the total and unbound isavuconazole pharmacokinetics and subsequently propose a dosage optimisation strategy | ||
| 520 | |a METHODS: A prospective multi-centre study in adult intensive care unit patients receiving isavuconazole was performed. Blood samples were collected on eight timepoints over one dosing interval between days 3-7 of treatment and optionally on one timepoint after discontinuation. Total and unbound isavuconazole pharmacokinetics were analysed by means of population pharmacokinetic modelling using NONMEM. The final model was used to perform simulations to assess exposure described by the area under the concentration-time curve and propose an adaptive dosing approach | ||
| 520 | |a RESULTS: Population pharmacokinetics of total and unbound isavuconazole were best described by an allometrically scaled two-compartment model with a saturable protein-binding model and interindividual variability on clearance and the maximum binding capacity. The median (range) isavuconazole unbound fraction was 1.65% (0.83-3.25%). After standard dosing, only 35.8% of simulated patients reached a total isavuconazole area under the concentration-time curve > 60 mg·h/L at day 14. The proposed adaptive dosing strategy resulted in an increase to 62.3% of patients at adequate steady-state exposure | ||
| 520 | |a CONCLUSIONS: In critically ill patients, total isavuconazole exposure is reduced and protein binding is highly variable. We proposed an adaptive dosing approach to enhance early treatment optimisation in this high-risk population | ||
| 520 | |a CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04777058 | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a isavuconazole |2 NLM | |
| 650 | 7 | |a 60UTO373KE |2 NLM | |
| 650 | 7 | |a Triazoles |2 NLM | |
| 700 | 1 | |a Mertens, Beatrijs |e verfasserin |4 aut | |
| 700 | 1 | |a Spriet, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Verweij, Paul E |e verfasserin |4 aut | |
| 700 | 1 | |a Schouten, Jeroen |e verfasserin |4 aut | |
| 700 | 1 | |a Wauters, Joost |e verfasserin |4 aut | |
| 700 | 1 | |a Debaveye, Yves |e verfasserin |4 aut | |
| 700 | 1 | |a Ter Heine, Rob |e verfasserin |4 aut | |
| 700 | 1 | |a Brüggemann, Roger J M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical pharmacokinetics |d 1993 |g 62(2023), 12 vom: 10. Dez., Seite 1701-1711 |w (DE-627)NLM000147567 |x 1179-1926 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2023 |g number:12 |g day:10 |g month:12 |g pages:1701-1711 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40262-023-01305-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2023 |e 12 |b 10 |c 12 |h 1701-1711 | ||